Watch for Andexxa, a New Anticoagulant Reversal Agent

July 2018

Andexxa (an-DEK-sah, inactivated recombinant factor Xa) will be a new, IV direct oral anticoagulant (DOAC) reversal agent.

Until now, the only reversal agent for the DOACs was Praxbind (idarucizumab). But it only inactivates Pradaxa (dabigatran)...a direct thrombin inhibitor.

Andexxa will be bigger news...it's an antidote for two factor Xa inhibitors, Eliquis (apixaban) or Xarelto (rivaroxaban).

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Infectious Diseases Ensure Patients With Gonorrhea Get Two Antibiotics
Anticoagulants Watch for Andexxa, a New Anticoagulant Reversal Agent
Diabetes Don't Use a Flozin Plus a GLP-1 Agonist for Most Diabetes Patients
Aspirin Put the Aspirin and NSAID Interaction in Perspective
Sunscreens Help Balance Competing Concerns About Sunscreens
Stroke Optimize Meds to Reduce Recurrent Stroke Risk
Crohn's Disease Be Ready to Help Your Crohn's Disease Patients Start Biologics
Women's Health Any OTC Levonorgestrel Product Is Okay for Emergency Contraception
Practice Set Patient Expectations for Home Genetic Tests
Respiratory & Allergy Don't Jump to Xhance for Nasal Polyps
Vaginal Infections Stick With Metronidazole for Most Women With Bacterial Vaginosis
Communication Improve Communication With Older Patients
Stroke Be Aware of the Latest Evidence With Acute Stroke Protocols
Practice Look for New Opportunities for IV-to-PO Conversions